Abstract:
Disclosed herein is a compound of formula (A), its salts, enantiomers, and diastereomers thereof; wherein, Rl and R2 can be (C1-C6) alkyl groups, a phenyl group, a (C5-C7) cycloalkyl groups; X and Y individually selected from H, -N02, -NH2, -OH, -halo, -CHO, -COOH, - COOR, boronic acid-potassium bifluoride boronate salts, boronate esters, aryl, substituted aryl, alkyl or aryl carbamoyl, substituted alkyl or aryl carbamoyl; phosphines(R3R3P) and phosphine oxide of the formula R3R3P=0, where R3 represents an aryl group that can be substituted by one or more (C1-C5) alkyl group, a (C5-C7) cycloalkyl group, (Cl- C4) alkoxy group or di (C1-C4) alkyl amino groups, cyclic hetero aryl group preferably, a 5 membered ring or a halogen.(The R3 groups are normally identical and preferably phenyl groups); wherein both X and Y can be substituted in ortho, para or meta position of the phenyl ring w.r.t the diacetal/ ketal functional group in compound A. The invention also discloses process for preparation of the same.
Abstract:
This invention discloses a novel pharmaceutical salt of Lenalidomide. More particularly, the invention discloses crystalline Trifluroacetic acid salt of Lenalidomide; polymorphic forms thereof and process for preparation thereof. The invention further discloses pharmaceutical composition comprising crystalline Trifluroacetic acid salt of Lenalidomide in association with one or more pharmaceutical excipients.
Abstract:
The present invention discloses sulphur functionalized polyurea composite of Formula (I) and Formula (II) that provides an insoluble solid support for effective removal of metal residues from solvent streams and other reservoirs and to the process for preparation of same thereof.
Abstract:
This invention discloses a novel pharmaceutical salt of Lenalidomide. More particularly, the invention discloses crystalline Trifluroacetic acid salt of Lenalidomide; polymorphic forms thereof and process for preparation thereof. The invention further discloses pharmaceutical composition comprising crystalline Trifluroacetic acid salt of Lenalidomide in association with one or more pharmaceutical excipients.
Abstract:
Disclosed herein is a highly safe and easily scalable process for the production of 7-Ethyl- 10-hydroxycamptothecin and its conversion to Irinotecan hydrochloride by total synthesis.
Abstract:
A novel process for making Renin inhibitors like Aliskiren is disclosed. Its novel intermediate compounds and method of making them are also disclosed.